Translating CRISPR genome editing into medicines
Editas Medicine is a leading gene editing company founded in 2013, HQ Cambridge Massachusetts. Translates CRISPR genome editing into medicines for serious diseases using CRISPR/Cas9 and Cas12a nucleases. Focus on hemoglobinopathies (sickle cell, beta thalassemia), cardiovascular diseases, and oncology. Went public February 2016.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free AccountBiopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Provides comprehensive molecular profiling and AI-driven precision oncology services for physicia...
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
